Management of hemolytic uremic syndrome - 02/02/12
, Jeffrey Saland 2, Martin Bitzan 3
Chantal Loirat, Hôpital Robert-Debré, service de néphrologie, 48, boulevard Serurier, 75019 Paris, France.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
This article has been published in an issue click here to access
Summary |
2011 has been a special year for hemolytic uremic syndrome (HUS): on the one hand, the dramatic epidemic of Shiga toxin producing E. coli – associated HUS in Germany brought the disease to the attention of the general population, on the other hand it has been the year when eculizumab, the first complement blocker available for clinical practice, was demonstrated as the potential new standard of care for atypical HUS.
Here we review the therapeutic options presently available for the various forms of hemolytic uremic syndrome and show how recent knowledge has changed the therapeutic approach and prognosis of atypical HUS.
El texto completo de este artículo está disponible en PDF.Esquema
 | Since the submission of the manuscript, the U.S. Food and Drug Administration (September 23, 2011) and the European Commission (November 29, 2011) have extended the therapeutic indication of Soliris® to include the treatment of pediatric and adult patients with aHUS. |
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.